| Penny Stocks blog and directory | ||||||||||||||||||
| Blog Preview | Search Engine Statistics | |||||||||||||||||
![]() | Indexed Pages: 387,000 | Backlinks: 114 | ||||||||||||||||
| Indexed Pages: 193 | Backlinks: 0 | |||||||||||||||||
| Indexed Pages: 0 | Backlinks: 138,908 | |||||||||||||||||
| Indexed Pages: 122,000 | Backlinks: 17,100 | |||||||||||||||||
| Indexed Pages: 123,000 | Backlinks: 128,000 | |||||||||||||||||
| ||||||||||||||||||
| Blog Details | ||||||||||||||||||
| Blog Directory Statistics | ||||||||||||||||||
| ||||||||||||||||||
| Alexa Web Ranking: 60,505 | ||||||||||||||||||
| Latest Blog Post from Penny Stocks blog and directory | ||||||||||||||||||
Dendreon Corporation (NASDAQ: DNDN) stock gained 33% shortly before yesterday's open and closed at $6.93. The fuss was created by news announcement stating that it has completed the study on the effect of its experimental drug Provenge. The drug proved to reduce the risk of death by 20% for men with advanced prostate cancer. Joel Sendek, analyst at Lazard Capital Markets, commented on the results: " read more in hotstocked.com | ||||||||||||||||||
| Subscribe to RSS Feed | ||||||||||||||||||
My Yahoo! Google NewsGator Stumbleupon PluckIT Rojo Bloglines My AOL Blogrolling ENewsblog NewsIsFree NetVibes del.icio.us Technorati Digg This FeedMailer | ||||||||||||||||||
| Other Related Blogs | ||||||||||||||||||
| Link Love - Link To US | ||||||||||||||||||
Or if you prefer use one of our linkware images? Click here | ||||||||||||||||||


